Experimental Obesity Drug Avoids Brain Effects That Troubled Predecessors

Published: Jul 12, 2010

EurekAlert! -- Stockholm, Sweden: A second-generation experimental anti-obesity and diabetes drug has shown promise in reducing body weight in rodents just as effectively as the predecessor rimonabant while avoiding the risk of psychiatric side effects that led to the withdrawal of rimonabant from the market and stopped further development of other brain-penetrating drugs of its type.

Back to news